CJC-1295 and Ipamorelin are structurally unrelated peptides that happen to be supplied together because of how their mechanisms complement each other — not because they share any chemical lineage. Understanding each one's structure separately is the starting point for understanding why the blend behaves the way it does.
CJC-1295 (No-DAC): a modified GHRH fragment
CJC-1295 is built on the sequence of growth-hormone-releasing hormone (GHRH), specifically the biologically active 1-29 fragment of the full 44-amino-acid hormone. Several amino-acid substitutions are introduced relative to native GHRH to increase resistance to enzymatic cleavage by proteases that would otherwise rapidly degrade the natural hormone in circulation. Notably, the version described here is the No-DAC form: it does not carry the Drug Affinity Complex — a maleimide group added in some CJC-1295 formulations specifically to bind circulating albumin and extend half-life. Without that addition, No-DAC CJC-1295 is the smaller, unmodified-half-life form of the stability-enhanced analog, with a molecular structure closer to the original GHRH(1-29) fragment than the albumin-binding variant.
Ipamorelin: a compact pentapeptide
Ipamorelin is a synthetic pentapeptide — five amino acids — designed to mimic the endogenous hormone ghrelin at the growth-hormone secretagogue receptor. Its short chain length and specific residue selection give it high selectivity for that one receptor, which is the structural basis for its comparatively clean pharmacological profile relative to earlier, larger secretagogue peptides that interact with multiple receptor types.
How both are manufactured
Both peptides are produced using solid-phase peptide synthesis (SPPS), a stepwise method in which amino acids are added one at a time to a chain anchored on an insoluble resin, then cleaved and purified once the full sequence is assembled. Background on how amino-acid sequence and chain assembly work more generally is covered in understanding amino acid sequences. After synthesis, each peptide is purified and verified independently before being combined and lyophilized together as the finished blend — confirmed by chromatographic separation and mass analysis, the complementary techniques explained in HPLC vs. mass spectrometry.
Purification and final form
Following synthesis and cleavage from the resin, each peptide is purified by reverse-phase HPLC to remove truncated or incorrectly coupled byproducts that inevitably form during stepwise synthesis, then lyophilized into a stable powder for long-term storage. Both CJC-1295 and Ipamorelin are water-soluble once reconstituted, though as with most peptides, the finished lyophilized powder — not the reconstituted solution — is the more stable long-term storage form for either component of the blend.
Why the structural difference matters for the blend
Because CJC-1295 and Ipamorelin differ substantially in size, charge, and stability, they are synthesized and purified as entirely separate production runs before being combined in a single lyophilized vial — there is no chemical reaction between the two peptides in solution or in powder form; the blend is a physical combination of two independently verified, structurally distinct molecules.
Product page: CJC-1295 (No-DAC) & Ipamorelin research blend.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.